The Information Technology Aided Relapse Prevention Programme in Schizophrenia: an extension of a mirror-design follow-up by Španiel, F et al.
The Information Technology Aided Relapse Prevention
Programme in Schizophrenia: an extension
of a mirror-design follow-up
F. S ˇpaniel,
1,2,3 P. Vohlı ´dka,
4 J. Koz ˇeny ´,
1,2,3 T. Nova ´k,
1,2,3 J. Hrdlic ˇka,
5 L. Motlova ´,
1,2,3 J. C ˇerma ´k,
1,2,3
C. Ho ¨schl
1,2,3
Introduction
The need for providing more efﬁcient healthcare ser-
vices, coupled with major advancements in informa-
tion and high-tech communication technology, has
led to novel approaches to medical treatment during
the last decade. E-health technologies combine the
use of electronic communication and information
technology in the healthcare for clinical, education
and administrative purposes.
The Information Technology Aided Relapse
Prevention Programme in Schizophrenia (ITAREPS),
developed by the Prague Psychiatric Centre in the
Czech Republic, presents a mobile phone-based
e-health solution for remote patient monitoring and
disease management in schizophrenia and psychotic
disorders in general.
The main incentive behind ITAREPS develop-
ment was emerging evidence that acute psychotic
state may result in certain pathophysiological pro-
cesses in the central nervous system (CNS) respon-
sible for deterioration of the overall clinical
condition (1). Increased number of psychotic
relapses contribute to a social decline and can
interfere with a treatment response (2–4). More-
over, available data suggest correlation of increased
relapse⁄hospitalisation rate with structural abnor-
malities of the CNS (5). There is also convincing
evidence of an association between duration of the
untreated psychosis and adverse clinical outcome,
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SUMMARY
Aims: Decreasing a number of hospital admissions is important for improving out-
comes for people with schizophrenia. The Information Technology Aided Relapse
Prevention Programme in Schizophrenia (ITAREPS) programme enables early phar-
macological intervention in psychosis by identiﬁcation of prodromal symptoms of
relapse using home telemonitoring via a phone-to-PC SMS platform. Methods:
This study was a 1-year extension of a previously published mirror-design follow-
up evaluation of programme clinical effectiveness. In total, 73 patients with psy-
chotic illness (45 patients from original sample and 28 newly added subjects)
collaborating with 56 family members participated in the clinical evaluation.
Results: There was a statistically signiﬁcant 77% decrease in the number of hos-
pitalisations during the mean 396.8 ± 249.4 days of participation in ITAREPS,
compared with the same time period before participation in ITAREPS (Wilcoxon-
signed ranks test, p < 0.00001), as well as signiﬁcantly reduced number of hospi-
talisation days when in the ITAREPS (2365 hospitalisation days before and
991 days after ITAREPS enrolment respectively, Wilcoxon-signed ranks test,
p < 0.003). Conclusion: The ITAREPS programme represents an effective tool in
the long-term treatment of patients with psychotic disorders.
What’s known
Studies published so far suggest that crisis
interventions such as increasing the dose of
antipsychotic medication, based on early detection
within a relapse prevention programme, reduce
readmission rates in schizophrenia. Previous
ﬁndings from ITAREPS mirror-image design follow-
up showed a statistically signiﬁcant 60%
decrease in the number of hospitalisations during
the mean 283.3 ± 111.9 days of participation in
ITAREPS compared with the same time period
before entering the programme (sign test,
p < 0.004).
What’s new
The ITAREPS enables early pharmacological
intervention in psychosis by identiﬁcation of
prodromes of relapse using home telemonitoring
via a phone-to-PC SMS platform. ITAREPS
demonstrated sustained effectiveness for 1 year
after the conclusion of the previous mirror-image
design follow-up, decreasing the total number of
hospitalisations by 77% and the number of
hospitalisation days by 58% respectively, during the
time spent in ITAREPS compared with a period of
equal length prior to ITAREPS enrolment.
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chotic state (6,7).
These ﬁndings emphasise the need for a decrease
in the number of relapses as one of the main goals
of long-term treatment of psychotic illness.
The Information Technology Aided Relapse Pre-
vention Programme in Schizophrenia-mediated
telemonitoring identiﬁes early warning symptoms of
an illness. It enables early pharmacological interven-
tion and helps to prevent relapses and recurrent hos-
pitalisations. Previous ﬁndings from a mirror-image
design (i.e. one group, uncontrolled, non-blind,
before-after design) follow-up evaluation of clinical
effectiveness of the ITAREPS programme in 45
patients with psychotic illness (8) showed a statisti-
cally signiﬁcant 60% decrease in the number of hos-
pitalisations during the mean 283.3 ± 111.9 days of
participation in ITAREPS compared with the same
time period before entering the programme (sign
test, p < 0.004).
The main aim of this clinical evaluation was to
conﬁrm sustained effectiveness of the programme,
one additional year after the conclusion of the previ-
ous mirror-image design follow-up.
Methods
Each participant, a patient and her⁄his family mem-
ber enrolled in the ITAREPS programme, completes
a 10-item Early Warning Signs Questionnaire
(EWSQ, patient and the family member version
respectively). Reporting on psychometric properties
and structure of EWSQ has been published elsewhere
(8,9). Reminder for the completion of the EWSQ is
sent weekly by an automated system to their mobile
phones as an SMS. Individual EWSQ scores are sent
by participants back to ITAREPS as an SMS. No spe-
ciﬁc training is provided for ITAREPS participants
except information detailed in the ITAREPS user
guide distributed to the programme participants.
If a total EWSQ score exceeds a given score
threshold, an automatically generated ALERT is
declared and a treating psychiatrist is notiﬁed by an
e-mail message. According to the Early Intervention
Algorithm (EIA), a part of ITAREPS, the presence of
early warning signs warrants an immediate increase
in baseline maintenance dose of antipsychotic by
20% within the next 24 h. However, data about nat-
ure of early intervention were not captured.
An ITAREPS web-based interface (http://www.
itareps.com) offers an authorised physician, a user-
friendly process to enter patient data. It also provides
summaries and continuous reporting on current clin-
ical status of each patient participating in the ITA-
REPS.
A total of 73 outpatients with psychotic disorders
were enrolled by their psychiatrists through 25 out-
patient facilities in the Czech and Slovak Republics
for routine clinical use of the programme. Forty-ﬁve
patients completed previously published study (8).
Additional 28 patients were added to this cohort.
There were no qualifying criteria for inclusion
except the diagnosis of psychotic illness. Patients ful-
ﬁlled International Classiﬁcation of Diseases (ICD)-10
criteria for diagnosis of schizophrenia, schizoaffective
disorder or acute polymorphic psychotic disorder
with or without symptoms of schizophrenia (Table 1).
Of the 73 patients, 56 had a participating family
member. Participation of a family member in
ITAREPS was highly recommended, albeit optional.
The following baseline patient data were obtained
and entered by psychiatrists: demographic data; diag-
nosis; illness history; Clinical Global Impression
Severity Scale (CGI-S) and current medication. Com-
pliance was evaluated by psychiatrists using a ques-
tionnaire with a 5-point scale [one = always and
ﬁve = never taking antipsychotic medication (10)].
As this follow-up used only clinical information
without speciﬁc patient identiﬁers and the proce-
dures required no deviation from standard clinical
practice, informed consent was not obtained from
participants. The protocol of ITAREPS programme
was approved by the Ethics Committee of the Prague
Psychiatric Centre.
Table 1 The demographic and clinical characteristics of
the patients
Mean (SD)
Age
Male (n = 40) 29.9 (6.7) years
Female (n = 33) 29.5 (9.4) years
Baseline CGI 2.7 (1.2)
Duration of illness 7.9 (5.3) years
Number of hospitalisations before
ITAREPS entry
2.9 (3.3)
n
Diagnosis
Schizophrenia 47 (64.4%)
Schizoaffective disorder 15 (20.5%)
Acute polymorphic psychotic disorder
with schizophrenia symptoms
10 (13.7%)
Acute polymorphic psychotic disorder
without schizophrenia symptoms
1 (1.4%)
Antipsychotic medication
No 5 (6.9%)
Yes 68 (93.1%)
ITAREPS, Information Technology Aided Relapse Prevention
Programme in Schizophrenia; CGI, Clinical Global Impression.
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The number of hospitalisations was assessed individ-
ually for each patient during the period of her⁄his
participation in ITAREPS programme compared with
equal period of time prior to ITAREPS enrolment.
In total, there were 14 hospitalisations during a
mean of 396.8 ± 249.4 days follow-up compared
with 60 hospitalisations during the same length of
time before entering the programme. The results
showed a statistically signiﬁcant reduction of 77% in
the number of hospitalisations during the ITAREPS
programme participation (Wilcoxon-signed ranks
test, Monte Carlo, exact test, two-tailed, Z = 4.86,
p < 0.00001).
There was a statistically signiﬁcant reduction of
58% in the number of hospitalisation days during
the programme participation compared with the
mirror period before the ITAREPS entry (in total
2365 hospitalisation days before the ITAREPS com-
pared with 991 days after the programme entry
respectively, Wilcoxon-signed ranks test, Monte Car-
lo, exact test, two-tailed, Z = 2.86, p < 0.003).
There was 100% decrease in the number of hospi-
talisations (from 25 to zero) in patients within highly
co-operative patient⁄family member pairs (n = 25,
34% of all patients) during the follow-up. The par-
ticipants¢ high co-operation was set up as at least
70% of the expected SMS with the EWSQ rating
were delivered to the system.
This ﬁnding remains unchanged from the previous
follow-up results where 100% decrease in the num-
ber of hospitalisations (from 13 to zero) was
observed in patients from highly co-operative
patient⁄family member pairs (n = 21, 47% of all
patients).
No signiﬁcant difference was found between
patients with hospitalisation and patients without
hospitalisation in the ITAREPS programme regarding
duration of illness, number of hospitalisations before
entering the ITAREPS, CGI-S rating at the baseline
ITAREPS visit, medication compliance, medication
formulation (depot vs. oral antipsychotic medica-
tion), length of participation in the ITAREPS pro-
gramme, number of ALERT messages, involvement
of a family member or separately assessed co-opera-
tion of a patient or a family member respectively. A
controlled randomised study should be warranted to
ﬁnd out what effect these variables have on effective-
ness of ITAREPS.
However, the group of patients without hospitali-
sation showed a signiﬁcantly higher proportion of
highly co-operative patient⁄family member pairs
compared with subjects with hospitalisation during
ITAREPS programme participation (Wilcoxon-signed
ranks test, Monte Carlo, exact test, two-tailed,
p = 0.009, test-speciﬁc a error level 0.015 – Tukey’s
adjustment for 11 primary end-points).
Discussion
The effectiveness of the ITAREPS programme, in
conjunction with its low set-up and operating costs,
makes ITAREPS an attractive option in the long-
term treatment and management of patients with
schizophrenia and psychotic disorders in general.
Albeit user-friendly and easy-to-understand system
with minimal eligibility requirements for patient
implying its utilizability in common clinical settings,
the programme applicability in severely ill, less com-
pliant subjects warrants further investigation.
The results of the clinical follow-up should be
interpreted with caution because of methodological
limitations of the mirror-image design (the absence
of a control group, lack of blinding and randomisa-
tion, inability to control for factors like patients’
decreasing risk of rehospitalisation over time). In
addition, although a speciﬁc pharmacological inter-
vention was recommended according to EIA, the
exact nature of the intervention during the ALERT
states could not be documented in this clinical evalu-
ation.
Therefore, a prospective, double-blind, randomised
trial with the ITAREPS programme is warranted to
conﬁrm these promising ﬁndings.
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